Propanc Biopharma, Inc.
PPCB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001517681
No open-market purchases or sales by Propanc Biopharma, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $71.5K in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Propanc Biopharma, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 5 | 6 | +1 |
| Shares | 128.9K | 462.4K | +333.5K (+258.7%) |
| Value | $69.5K | $48.7K | −$20.8K (−29.9%) |
New holders (4)
Institutions that held Propanc Biopharma, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 182,614 | $19.4K | 0.00% |
| Jane Street Group, LLC | 143,212 | $15.2K | 0.00% |
| Virtu Financial LLC | 40,748 | $4.00K | 0.00% |
| Sassicaia Capital Advisers LLC | 16,000 | $1.70K | 0.00% |
Sold out (3)
Institutions that held Propanc Biopharma, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Two Sigma Securities, LLC | 25,483 | $13.7K |
| Two Sigma Investments, LP | 16,257 | $8.72K |
| Morgan Stanley | 1 | $1 |